FDG PET/CT in oncology: “raising the bar”

Present and future of FDG-PET/CT in ovarian cancer

“…Recently, integrated PET/ CT, in which a full-ring-detector clinical PET scanner and multidetector row helical CT scanner are combined, has made it possible to acquire both metabolic and anatomic imaging data using a single device in a single diagnostic session and provides precise anatomic localization of suspicious areas of increased FDG uptake [3]. In the clinical setting, FDG-PET/CT has achieved a significant improvement in diagnostic accuracy and exerted a considerable impact on patient management including diagnosis, staging, optimization of treatment, restaging, therapy monitoring, and prognostic prediction of various malignant tumors [4,5]. We herein review the current and future role of FDG-PET/CT in the management of ovarian cancer, discussing its usefulness and limitations in the imaging of these patients.…”

Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: A 3-arm randomized phase II trial

“…An important prerequisite of this hypothesis is the correct identification of the radiotherapy target. We hypothesized that positron emitting tomography (PET) with 18-[F]-fluoro-D-glucose ( 18 F-FDG), a commonly used surrogate for tumor cell burden and inflammation [25], can define our radiotherapy target and direct dose prescription in accordance to tumor heterogeneity. Intratumor regions of increased radioresistance, presumably indicated by higher standardized uptake value (SUV) of 18 F-FDG [1,18,22], receive escalated dose levels, whereas radiation-sensitive regions outside the target receive conventional or even de-escalated dose levels.…”

Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer

“…Radionuclide-labeled tracer or molecular probes targeting tumor cells effectively identify tumor lesions that are challenging to detect with traditional imaging methods, and PET/CT has become a powerful tool for the clinical diagnosis of tumors (22). At present, 11 C-choline and other cell metabolic substrates are used as PET/CT tracers, which have achieved a certain efficacy in the diagnosis of Pca (23,24). However, these tracers lack specificity to Pca, and it is challenging to distinguish between primary and metastatic Pca, which is prone to false-positive results of benign prostatic hyperplasia and prostatitis lesions (23,24).…”

“…At present, 11 C-choline and other cell metabolic substrates are used as PET/CT tracers, which have achieved a certain efficacy in the diagnosis of Pca (23,24). However, these tracers lack specificity to Pca, and it is challenging to distinguish between primary and metastatic Pca, which is prone to false-positive results of benign prostatic hyperplasia and prostatitis lesions (23,24). Therefore, it is essential to identify an efficient and specific molecular probe to improve the sensitivity and accuracy of PET/CT in the diagnosis of Pca, which may be capable of effectively providing early diagnosis, preoperative staging, postoperative recurrence and restaging and postoperative efficacy evaluation and detection.…”